08-13-2013, 02:39 PM
This particular study is actually intriguing. Here’s how I partially summarized it:
HVTN means HIV Vaccine Trial Network. This was a study conducted in 2009 as an exploratory clinical trial to investigate the HIV Vaccine regimen. The National Institute of Allergy and Infectious Diseases (NIAID) conducted the trial.
It had several goals which were to test if the vaccine regimen:
a. could lower the amount of viral load or blood HIV of people who were later infected with the virus, but vaccinated beforehand;
b. was safe, as previous trials showed to be so;
c. could prevent HIV infection;
d. had similar results compared to the RIV 144 HIV Vaccine trial in Thailand; and
e. had promising effects to the monkey equivalent HIV infection.
The trial was halted after an independent data and safety monitoring board (DSMB) discovered on April 22, 2013 that it did not lower viral load among recipients who were later infected and did not prevent the occurrence of HIV infection.
Interestingly, the regimen actually had two kinds of vaccines administered. One is to prime the immune system, while the other was designed to boost such. This, in turn, makes the body produce several types of immune responses when compared with other vaccine regimens using only one type.
For eight weeks, there will be three immunizations given. Not only that, a weakened adenovirus type 5 (Ad5) is administered as a recombinant boosting vaccine to further stimulate the immune system. Such viruses are the cause of common colds, but both the Ad5 and the HIV immunizations, for years, have been proven not to cause an infection.
The HIV particles used for the immunizations are not made from a weakened (attenuated), live, or killed virus. They are only pieces of the virus, but are lacking enough to cause AIDS.
The study team had 2,504 HIV-negative male enrollees who were circumcised, had no antibodies to the Ad5 virus, and have had sexual contact with men. Their ages were between 18-50 years old and all of them resided in the United States.
For more info, you may go directly to their website:
http://www.niaid.nih.gov/news/QA/Pages/H...a2013.aspx
HVTN means HIV Vaccine Trial Network. This was a study conducted in 2009 as an exploratory clinical trial to investigate the HIV Vaccine regimen. The National Institute of Allergy and Infectious Diseases (NIAID) conducted the trial.
It had several goals which were to test if the vaccine regimen:
a. could lower the amount of viral load or blood HIV of people who were later infected with the virus, but vaccinated beforehand;
b. was safe, as previous trials showed to be so;
c. could prevent HIV infection;
d. had similar results compared to the RIV 144 HIV Vaccine trial in Thailand; and
e. had promising effects to the monkey equivalent HIV infection.
The trial was halted after an independent data and safety monitoring board (DSMB) discovered on April 22, 2013 that it did not lower viral load among recipients who were later infected and did not prevent the occurrence of HIV infection.
Interestingly, the regimen actually had two kinds of vaccines administered. One is to prime the immune system, while the other was designed to boost such. This, in turn, makes the body produce several types of immune responses when compared with other vaccine regimens using only one type.
For eight weeks, there will be three immunizations given. Not only that, a weakened adenovirus type 5 (Ad5) is administered as a recombinant boosting vaccine to further stimulate the immune system. Such viruses are the cause of common colds, but both the Ad5 and the HIV immunizations, for years, have been proven not to cause an infection.
The HIV particles used for the immunizations are not made from a weakened (attenuated), live, or killed virus. They are only pieces of the virus, but are lacking enough to cause AIDS.
The study team had 2,504 HIV-negative male enrollees who were circumcised, had no antibodies to the Ad5 virus, and have had sexual contact with men. Their ages were between 18-50 years old and all of them resided in the United States.
For more info, you may go directly to their website:
http://www.niaid.nih.gov/news/QA/Pages/H...a2013.aspx
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)